Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock following its Q3 earnings release.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on ...

- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with ...

Infectious meningoencephalitis, characterized by inflammation of both the brain and adjacent meninges, is caused by a variety ...

The FDA has issued a CRL to Biohaven regarding the NDA for troriluzole for the treatment of adults with spinocerebellar ataxia.

Mental health disorders are increasingly prevalent in adults aged 55 and above, with nearly 19% experiencing conditions like depression and anxiety. These issues often go unnoticed due to symptoms ...

Guth has Friedreich’s Ataxia and chose to raise money at Happy Place Nutrition for Friedreich’s Ataxia Research Alliance ...

Neurocrine Biosciences, Inc. today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder ...

Scientists at Brigham and Women's Hospital and Harvard Medical School have developed a targeted genetic test to improve ...

The United States is facing a demographic shift as the population of older adults grows rapidly, with the proportion of ...

Temporarily anesthetizing the retina briefly reverts the activity of the visual system to that observed in early development ...

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer ASCO–Society for Integrative Oncology (SIO) Guidelines provide ...